GlassScriptPhysician profile
Briahnnon Long
NPI 1598364911
$2,600.83
in general payments reported to CMS, 2019-2025
22 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $879 · 2024: $837 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.08 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.74 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $380.61 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $295.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $254.42 | 2022-2025 | |
| Glaxosmithkline, LLC. | $147.43 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $129.11 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $117.20 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.19 | 2023-2025 | Jardiance |
| Pfizer INC. | $108.96 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.86 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $86.44 | 2024 | Gemtesa |
| Vanda Pharmaceuticals INC. | $85.84 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $58.15 | 2022-2023 | Verquvo |
| Mozarc Medical US LLC | $33.14 | 2023 | Chameleon |
| Mayne Pharma Commercial LLC | $31.66 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $24.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $22.07 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $20.40 | 2024 | Auvelity |
| Amgen INC. | $17.73 | 2024 | Repatha, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.95 | 2023 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $16.14 | 2023 | Trintellix |
| Shield Therapeutics INC | $15.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Briahnnon Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.